Publications by authors named "Alberto Verlicchi"

Claim this Profile
G
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients.
Matteo Canale, Alessandra Virga, Davide Angeli, Eugenio Fonzi, Letizia Gnetti, Alberto Verlicchi

Lung Cancer (Auckl)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.
Kalliopi Andrikou, Paola Ulivi, Elisabetta Petracci, Irene Azzali, Federica Bertolini, Alberto Verlicchi

Diagnostics (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.
Nicola Gentili, William Balzi, Flavia Foca, Valentina Danesi, Mattia Altini, Alberto Verlicchi

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
Kalliopi Andrikou, Tania Rossi, Alberto Verlicchi, Ilaria Priano, Paola Cravero

Int J Mol Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer.
Alberto Verlicchi, Matteo Canale, Elisa Chiadini, Paola Cravero, Milena Urbini

Life (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Alberto Verlicchi

Sci Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Giuseppe Bronte, Alberto Verlicchi, Serena De Matteis, Alice Rossi, Alessandra Affatato

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Giuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, Alberto Verlicchi, Maurizio Puccetti

Lung Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Mutation Confers Worse Prognosis in -Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs.
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Giuseppe Bronte, Elisa Chiadini, Alberto Verlicchi

J Clin Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New generation anaplastic lymphoma kinase inhibitors.
Angelo Delmonte, Marco Angelo Burgio, Alberto Verlicchi, Giuseppe Bronte, Paola Cravero

Transl Lung Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Masaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, David Lligé, Imane Chaib, Alberto Verlicchi

Cell Commun Signal· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.
Serena De Matteis, Matteo Canale, Alberto Verlicchi, Giuseppe Bronte, Angelo Delmonte

J Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Giuseppe Bronte, Paola Ulivi, Alberto Verlicchi, Paola Cravero, Angelo Delmonte

Lung Cancer (Auckl)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Imane Chaib, Niki Karachaliou, Sara Pilotto, Jordi Codony Servat, Xueting Cai, Alberto Verlicchi

J Natl Cancer Inst· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Chiara Lazzari, Niki Karachaliou, Vanesa Gregorc, Alessandra Bulotta, Maria Gonzalez-Cao, Alberto Verlicchi

Expert Rev Respir Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER3 as a Therapeutic Target in Cancer.
Niki Karachaliou, Chiara Lazzari, Alberto Verlicchi, Aaron E Sosa, Rafael Rosell

BioDrugs· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Paola Ulivi, Elisa Chiadini, Claudio Dazzi, Alessandra Dubini, Matteo Costantini, Alberto Verlicchi

Clin Lung Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Claudia Casanova, Alberto Verlicchi, Valentina Mazza, Claudio Dazzi

Future Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cells in small cell lung cancer.
Jordi Codony-Servat, Alberto Verlicchi, Rafael Rosell

Transl Lung Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Alberto Verlicchi

Sci Rep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Paola Ulivi, Angelo Delmonte, Elisa Chiadini, Daniele Calistri, Maximilian Papi, Alberto Verlicchi

Int J Mol Sci· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Claudio Dazzi, Anna Cariello, Claudia Casanova, Alberto Verlicchi, Marco Montanari

Clin Lung Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis